Chee Kong Choo
Director, 10% Owner · CytoMed Therapeutics Ltd
IndividualBuying only
- 2026
- Jul 25, 2026
- 3
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Chee Kong Choo's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Framework Ventures IV L.P. - $42.62M in SDEV purchases and sales in the last 12 months
- Helen Torley - $42.15M in HALO purchases and sales in the last 12 months
- Susan E. Burwig - $41.11M in MEDP purchases and sales in the last 12 months
- Mark Hancock - $40.97M in PACS purchases and sales in the last 12 months
- Gary S. Guthart - $40.57M in ISRG purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $40.00M in AKTS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Chee Kong Choo?
Chee Kong Choo is a corporate insider, tracked as Director, 10% Owner of CytoMed Therapeutics Ltd (GDTC). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Chee Kong Choo last file a Form 4?
The most recent primary Form 4 on record is dated 25 July 2026, one of 3 filings going back to 2026.
Has Chee Kong Choo been buying or selling stock?
Recorded transactions: 5 open-market purchases ($729K) and 0 open-market sales across all tracked filings.
